10th International Congress on Peritoneal Surface Malignancies

Course Description

In the past decade, the treatment of peritoneal metastases has gained interest from oncologic communities around the world. During the 1990’s, the first pioneering centers began treating patients with hyperthermic intraperitoneal chemotherapy (HIPEC). Prior to HIPEC, patients were treated with palliative support and only guaranteed a few months to live. Today, if a patient with peritoneal metastases is provided with proper treatment, the survival increases to an average of several years and improved outcomes are reported every day. The 2016 PSOGI congress’s mission is to provide clinical and scientific information on peritoneal surface malignancies and to create awareness regarding innovative treatments that will improve the quality of life for patients. The target audience includes healthcare practitioners in the field of surgical oncology, clinical oncology, gastroenterology, radiology, and gynecology. The program will also include a satellite meeting related to nurses in the field. This two and a half day conference is carefully balanced to cover the wide range of topics on peritoneal metastases. It will feature key note lectures, didactic sessions, debates, meet the professor sessions with case presentations interspersed where appropriate. Additionally, the meeting will consist of extended discussions among the elite panel and extensive audience participation.  Abstract submissions and poster presentations will also be included in the meeting.

Learning Objectives

• Utilize available data to determine optimal treatment options including Cytoreduction surgery plus Heated Intraperitoneal Chemotherapy (HIPEC) for patients with peritoneal metastases (colorectal, gastric cancer, ovarian cancer, apendiceal cancer, peritoneal mesothelioma)
• List, classify and utilize quantitative prognostic indicators to select patients who will most likely benefit from cytoreductive surgery with HIPEC
• Utilize the appropriate clinical pathways, patient protocols, and surgical procedures as recommended by a panel of international experts to optimize patient care
• Evaluate the potential efficacy of drugs for use in intraperitoneal or intravenous administrations in the treatment of peritoneal metastases with special emphasis on chemotherapy treatments used in the operating room
• Improve patient selection, surgical technique and management and standardized HIPEC regiments which will result in improved patient outcomes
• Identify patients at high risk for carcinomatosis or with low volume disease at the time of primary cancer treatment, review them in a multidisciplinary team meeting and study/treat the appropriate patients with CRS and HIPEC

Target Audience

This conference is intended for surgical and medical oncologists, surgical oncology nurses, surgical technicians, perfusionists, and other healthcare professionals interested in peritoneal surface oncology.